Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous daratumumab in combination with standard multiple myeloma regimens
2017-004203-41Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall Response Rate (ORR) and Very Good Partial Response (VGPR) or better rate. Status: unknown.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-004203-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004203-41.